Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202711 | 0.93 | CES2 (0.53) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL2198986 | 0.90 | CES2 (0.58) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL29281908 | 0.87 | — | — | |
| SCHEMBL2197391 | 0.86 | KMT2A (0.40) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL6113076 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL573198 | 0.83 | CES2 (0.50) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL28209666 | 0.81 | — | — | |
| SCHEMBL30068399 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2HTTKMT2ATDP1ALDH1A1 | |
| SCHEMBL382048 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2HTTKMT2ATDP1CES2 | |
| SCHEMBL1481528 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7740826-B2 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2010-06-22 | — | — | US | claimed |
| US-20090306427-A1 | Chemical Functionalization of Carbon Nanotubes | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2009-12-10 | — | — | US | claimed |
| EP-1989143-A1 | CHEMICAL FUNCTIONALIZATION OF CARBON NANOTUBES | National Research Council of Canada (CA) | 2008-11-12 | — | — | EP | claimed |
| WO-2007098578-A1 | CHEMICAL FUNCTIONALIZATION OF CARBON NANOTUBES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2007-09-07 | — | — | WO | claimed |
| US-20070098620-A1 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2007-05-03 | — | — | US | claimed |
| US-20040223900-A1 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2004-11-11 | — | — | US | claimed |
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3087060-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-7976816-B2 | Method for functionalizating carbon naontubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100222536-A1 | Method for Functionalizating Carbon Naontubes Utilizing Peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-7740826-B2 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090306427-A1 | Chemical Functionalization of Carbon Nanotubes | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2009-12-10 | — | — | US | disclosed |
| EP-1989143-A1 | CHEMICAL FUNCTIONALIZATION OF CARBON NANOTUBES | National Research Council of Canada (CA) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007098578-A1 | CHEMICAL FUNCTIONALIZATION OF CARBON NANOTUBES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2007-09-07 | — | — | WO | disclosed |
| US-20070098620-A1 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2007-05-03 | — | — | US | disclosed |
| US-7125533-B2 | decomposing an acyl peroxide to form carbon-centered free radicals and reacting the carbon-centered free radicals with the carbon nanotube to form a functionalized carbon nanotube | WILLIAM MARSH RICE UNIVERSITY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040223900-A1 | Method for functionalizing carbon nanotubes utilizing peroxides | WILLIAM MARSH RICE UNIVERSITY (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE3A | SMN1; SMN2 204/4885HTT 4240/4885KMT2A 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.